Characterization of monoclonal antibodies to human soluble MD-2 protein

Suganya Viriyakosol1, Paul B McCray, Mark E Ashbaugh

  • 1Veterans Medical Research Foundation, San Diego, California, USA. sviriyak@ucsd.edu

Hybridoma (2005)
|January 6, 2007
PubMed

Insights

Researchers developed new monoclonal antibodies (MAbs) to study MD-2, a key molecule in Toll-like receptor 4 (TLR4) activation. These antibodies detected soluble MD-2 (sMD-2) in sepsis patients, showing increased levels in disease.

Area of Science:

  • Immunology
  • Molecular Biology

Background:

  • Toll-like receptors (TLRs) are crucial for innate immunity, recognizing pathogen-associated molecular patterns (PAMPs).
  • Toll-like receptor 4 (TLR4) signaling requires the adapter molecule MD-2, which exists in cell-associated and soluble forms.
  • Understanding MD-2's distribution and function is vital for studying TLR4-mediated immune responses.

Purpose of the Study:

  • To generate and characterize monoclonal antibodies (MAbs) against soluble MD-2 (sMD-2).
  • To utilize these MAbs for studying MD-2 expression and its role in health and disease, particularly sepsis.

Main Methods:

  • Production of MAbs against baculovirally expressed sMD-2.
  • Characterization using ELISA, Western blotting, and inhibition assays for LPS binding.
  • Application of a specific MAb in ELISA to quantify sMD-2 levels in human sera.

Main Results:

  • Eleven MAbs were generated and characterized, with some showing specificity for MD-2 oligomers.
  • MAbs suitable for immunofluorescence staining of TLR4/MD-2 expressing cells were identified.
  • Serum sMD-2 levels were significantly elevated in sepsis patients compared to healthy individuals and non-sepsis patients.

Conclusions:

  • The developed MAbs are valuable tools for investigating MD-2 expression and function.
  • Elevated serum sMD-2 levels are a potential biomarker for sepsis.
  • These antibodies will advance research into TLR4-MD-2 complex roles in immunity and disease pathogenesis.